NYSE:EBS - Emergent BioSolutions Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $92.25
  • Forecasted Upside: 76.66 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$52.22
▲ +2.74 (5.54%)

This chart shows the closing price for EBS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Emergent BioSolutions Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EBS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EBS

Analyst Price Target is $92.25
▲ +76.66% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Emergent BioSolutions in the last 3 months. The average price target is $92.25, with a high forecast of $120.00 and a low forecast of $64.00. The average price target represents a 76.66% upside from the last price of $52.22.

This chart shows the closing price for EBS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Emergent BioSolutions. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2021Chardan CapitalLower Price TargetBuy$92.00 ➝ $75.00Low
11/8/2021BenchmarkDowngradeBuy ➝ HoldHigh
5/11/2021ArgusReiterated RatingBuy ➝ HoldN/A
5/5/2021Wells Fargo & CompanyLower Price Target$70.00 ➝ $64.00Low
5/5/2021ArgusDowngradeBuy ➝ HoldHigh
4/30/2021Chardan CapitalLower Price TargetBuy$112.00 ➝ $92.00Medium
4/30/2021BenchmarkLower Price TargetHold ➝ Buy$150.00 ➝ $120.00Medium
4/14/2021GuggenheimLower Price TargetBuy$130.00 ➝ $110.00Medium
4/7/2021BenchmarkInitiated CoverageBuy$150.00Low
2/24/2021Chardan CapitalUpgradeNeutral ➝ Buy$112.00Low
2/19/2021Chardan CapitalDowngradeBuy ➝ Neutral$112.00High
1/8/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$110.00High
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
7/31/2020Chardan CapitalBoost Price TargetBuy$86.00 ➝ $112.00High
7/17/2020Cantor FitzgeraldBoost Price TargetOverweight$85.00 ➝ $110.00High
7/2/2020Wells Fargo & CompanyBoost Price TargetOverweight$85.00 ➝ $93.00Medium
6/8/2020Chardan CapitalReiterated RatingBuy$86.00Low
6/8/2020Cantor FitzgeraldLower Price TargetOverweight$86.00 ➝ $85.00High
6/8/2020GuggenheimLower Price TargetBuy$101.00 ➝ $87.00High
6/2/2020GuggenheimBoost Price Target$81.00 ➝ $101.00Low
6/1/2020Chardan CapitalReiterated RatingBuy$86.00High
5/6/2020ArgusBoost Price TargetBuy$67.00 ➝ $90.00Low
5/1/2020Cantor FitzgeraldBoost Price TargetOverweight$75.00 ➝ $86.00High
5/1/2020Chardan CapitalBoost Price TargetBuy$71.00 ➝ $86.00High
4/30/2020Wells Fargo & CompanyBoost Price TargetOverweight$75.00 ➝ $85.00Low
4/24/2020Chardan CapitalReiterated RatingBuy$71.00High
3/12/2020CowenInitiated CoverageHold$67.00Medium
3/1/2020CowenReiterated RatingHold$67.00Low
2/25/2020Wells Fargo & CompanyBoost Price TargetOverweight$66.00 ➝ $75.00Medium
11/25/2019CowenReiterated RatingHold$67.00High
11/22/2019Cantor FitzgeraldReiterated RatingOverweight$75.00High
11/7/2019Wells Fargo & CompanyReiterated RatingBuyMedium
11/7/2019Chardan CapitalReiterated RatingBuy$71.00High
11/7/2019CowenReiterated RatingHold$67.00High
9/12/2019GuggenheimInitiated CoverageBuy$65.00Low
9/4/2019LaidlawSet Price TargetBuy$72.00Low
9/4/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$61.00 ➝ $64.00High
9/3/2019Chardan CapitalSet Price TargetBuy$71.00Low
7/31/2019CowenReiterated RatingHold$60.00High
5/10/2019Wells Fargo & CompanyLower Price TargetMarket Perform$61.00Medium
5/3/2019CowenReiterated RatingHold$60.00High
5/2/2019Cantor FitzgeraldReiterated RatingBuy$75.00High
4/21/2019Cantor FitzgeraldReiterated RatingBuy$75.00Medium
4/2/2019Wells Fargo & CompanySet Price TargetHold$68.00Low
3/1/2019Wells Fargo & CompanySet Price TargetHold$68.00High
2/22/2019Chardan CapitalSet Price TargetBuy$71.00High
1/25/2019Cantor FitzgeraldSet Price TargetBuy$75.00Low
1/4/2019Cantor FitzgeraldSet Price TargetBuy$75.00High
12/13/2018Cantor FitzgeraldSet Price TargetBuy$75.00High
12/12/2018Wells Fargo & CompanySet Price TargetHold$65.00High
11/20/2018CowenReiterated RatingHold$64.00Low
11/9/2018ArgusSet Price TargetBuy$80.00Low
11/2/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $75.00Medium
11/2/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy$60.00 ➝ $75.00High
9/11/2018Cantor FitzgeraldSet Price TargetBuy$68.00Low
9/11/2018ArgusBoost Price TargetBuy ➝ Average$70.00Low
9/4/2018Chardan CapitalBoost Price TargetBuy ➝ Buy$60.00 ➝ $66.00Medium
8/29/2018CowenReiterated RatingHold$49.00Low
8/29/2018Wells Fargo & CompanySet Price TargetMarket Perform ➝ Hold$61.00 ➝ $65.00High
8/28/2018Cantor FitzgeraldSet Price TargetBuy$62.00Low
8/10/2018Wells Fargo & CompanySet Price TargetHold$61.00N/A
8/9/2018Cantor FitzgeraldSet Price TargetBuy$62.00Low
8/3/2018Chardan CapitalBoost Price TargetBuy$53.00 ➝ $57.00High
8/2/2018Cantor FitzgeraldReiterated RatingBuy$62.00High
6/14/2018Cantor FitzgeraldReiterated RatingOverweightMedium
6/13/2018ArgusInitiated CoverageBuy$62.00High
6/11/2018Cantor FitzgeraldInitiated CoverageBuy$62.00Medium
4/25/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Market PerformHigh
4/24/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$56.00High
2/27/2018Singular ResearchBoost Price TargetBuy ➝ Buy$45.00 ➝ $60.00Medium
1/24/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$55.00Low
1/16/2018Chardan CapitalBoost Price TargetBuy$47.00 ➝ $53.00Medium
9/30/2017Wells Fargo & CompanyReiterated RatingOutperform$41.00 ➝ $43.00Medium
1/30/2017Chardan CapitalReiterated RatingBuy$47.00N/A
(Data available from 1/17/2017 forward)

News Sentiment Rating

0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/21/2021
  • 4 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
8/20/2021
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/19/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/19/2021
  • 2 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
11/18/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/17/2022

Current Sentiment

  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Emergent BioSolutions logo
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.
Read More

Today's Range

Now: $52.22
Low: $49.01
High: $52.28

50 Day Range

MA: $43.57
Low: $35.09
High: $52.22

52 Week Range

Now: $52.22
Low: $29.88
High: $127.20

Volume

684,660 shs

Average Volume

665,090 shs

Market Capitalization

$2.81 billion

P/E Ratio

12.43

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Emergent BioSolutions?

The following equities research analysts have issued research reports on Emergent BioSolutions in the last year: Argus, Benchmark Co., Chardan Capital, Guggenheim, TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for EBS.

What is the current price target for Emergent BioSolutions?

4 Wall Street analysts have set twelve-month price targets for Emergent BioSolutions in the last year. Their average twelve-month price target is $92.25, suggesting a possible upside of 76.7%. Benchmark Co. has the highest price target set, predicting EBS will reach $120.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $64.00 for Emergent BioSolutions in the next year.
View the latest price targets for EBS.

What is the current consensus analyst rating for Emergent BioSolutions?

Emergent BioSolutions currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EBS will outperform the market and that investors should add to their positions of Emergent BioSolutions.
View the latest ratings for EBS.

What other companies compete with Emergent BioSolutions?

How do I contact Emergent BioSolutions' investor relations team?

Emergent BioSolutions' physical mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company's listed phone number is (240) 631-3200 and its investor relations email address is [email protected] The official website for Emergent BioSolutions is www.emergentbiosolutions.com.